Soligenix, Inc. filed a prospectus supplement on June 26, 2026, to increase the maximum aggregate offering amount of common stock issuable under its At Market Issuance Sales Agreement with Rodman & Renshaw LLC by an additional $2,500,000. The company previously sold approximately $6,234,000 of shares of common stock under the own Sales Agreement. Soligenix, Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic solutions for neglected and orphan diseases.

On June 10, 2026, Soligenix received a Nasdaq Bid Price Notice stating it is non-compliant with the $1.00 minimum bid price requirement; the company has until December 7, 2026, to regain compliance. On June 11, 2026, the Board terminated the HyBryte development program following a Phase 3 FLASH2 trial recommendation of futility, estimating wind-down costs of approximately $70,000. Consequently, Dr. Richard C. Straube ceased serving as Consulting Chief Medical Officer, with responsibilities transitioning to Medical Director Dr. Christopher Pullion. The company will continue evaluating strategic options and other pipeline programs, including dusquetide for Behçet’s Disease. Soligenix is a biotechnology company that develops therapeutic products for various diseases.